109451
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
SLC7A11 在肿瘤进展中的作用及铁死亡相关调控机制
Authors Zhang X, Zhang Y, Wei J, Li X, Jiang A, Shen Y, Hou Y, Liu Q
Received 4 July 2025
Accepted for publication 7 October 2025
Published 15 October 2025 Volume 2025:17 Pages 2393—2401
DOI https://doi.org/10.2147/CMAR.S551549
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Chien-Feng Li
Xizheng Zhang,1,2 Yao Zhang,1,2 Jiayu Wei,1,2 Xuyan Li,3 Anqi Jiang,1,4– 6 Ying Shen,1,4– 6 Yongzhong Hou,1,2 Qian Liu1,4– 6
1Department of Oncology, Wujin Hospital Affiliated with Jiangsu University, Changzhou, Jiangsu Province, 213017, People’s Republic of China; 2School of Life Science, Jiangsu University Zhenjiang, Zhenjiang, Jiangsu, 212013, People’s Republic of China; 3Mangrove Institute, Lingnan Normal University, Zhanjiang, 524048, People’s Republic of China; 4Department of Oncology, the Wujin Clinical College of Xuzhou Medical University, Changzhou, Jiangsu Province, 213017, People’s Republic of China; 5Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu Province, 221004, People’s Republic of China; 6Changzhou Key Laboratory of Molecular Diagnostics and Precision Cancer Medicine / Wujin Institute of Molecular Diagnostics and Precision Cancer Medicine of Jiangsu University, Changzhou, Jiangsu Province, 213017, People’s Republic of China
Correspondence: Yongzhong Hou, School of Life Science Jiangsu University Zhenjiang, Zhenjiang, Jiangsu Province, 213017, People’s Republic of China, Email houyz@ujs.edu.cn Qian Liu, Department of Oncology, Wujin Hospital Affiliated with Jiangsu University, Changzhou, Jiangsu Province, 213017, People’s Republic of China, Email liuqian@wjrmyy.cn
Abstract: SLC7A11 (xCT) is a key subunit of the cysteine/glutamate transporter (system xc −), which is crucial for maintaining cellular redox homeostasis (especially glutathione synthesis) and regulating Ferroptosis. It is highly expressed in various malignant tumors and is a key factor leading to treatment resistance, making it an important anti-cancer target. This review systematically summarizes the complex multi-level regulatory network of SLC7A11: at the transcriptional level, key factors form precise regulatory hubs: the KEAP1/NRF2 pathway directly activates SLC7A11 transcription, endowing cancer cells with antioxidant and anti ferroptotic abilities; P53 acts as a core inhibitory factor, and its activity state (activated by STEAP3 iron overload or regulated by Gankyrin/DM2 degradation) directly determines the intensity of inhibition of SLC7A11; ATF4 integrates endoplasmic reticulum stress, oxidative damage, and epigenetic signals (such as SIRT3/KDM3B/KDM4A), and bidirectionally regulates SLC7A11 transcription. Epigenetic regulation involves RNA m6A modification (ALKBH5/FTO reduces stability, METTL3/IGF2BP3 enhances stability) and histone modification (BAP1/PRC1 inhibits through H2Aub). After translation, the stability of SLC7A11 protein is strictly regulated by ubiquitination (SOCS2/HECTD3 promotes degradation, OTUB1/TCF12 inhibits degradation) and palmitoylation (ZDHHC8/DUXAP8 antagonizes degradation). Of particular importance is that non coding RNAs indirectly release their inhibition of SLC7A11 mRNA by acting as “molecular sponges” to adsorb specific miRNAs, profoundly affecting tumor progression and resistance to ferroptosis. This study reveals how cancer cells abnormally upregulate SLC7A11 by hijacking multi-level mechanisms, gaining strong antioxidant/anti ferroptotic abilities, which are the core basis for their survival, proliferation, and resistance to treatment. This study also identified SLC7A11 as a convergence point for multiple key pathways, making it an ideal hub target for intervening in cancer and overcoming drug resistance.
Keywords: SLC7A11, ferroptosis, non-coding RNA, TP53, epigenetic regulation
1Department of Oncology, Wujin Hospital Affiliated with Jiangsu University, Changzhou, Jiangsu Province, 213017, People’s Republic of China; 2School of Life Science, Jiangsu University Zhenjiang, Zhenjiang, Jiangsu, 212013, People’s Republic of China; 3Mangrove Institute, Lingnan Normal University, Zhanjiang, 524048, People’s Republic of China; 4Department of Oncology, the Wujin Clinical College of Xuzhou Medical University, Changzhou, Jiangsu Province, 213017, People’s Republic of China; 5Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu Province, 221004, People’s Republic of China; 6Changzhou Key Laboratory of Molecular Diagnostics and Precision Cancer Medicine / Wujin Institute of Molecular Diagnostics and Precision Cancer Medicine of Jiangsu University, Changzhou, Jiangsu Province, 213017, People’s Republic of China
Correspondence: Yongzhong Hou, School of Life Science Jiangsu University Zhenjiang, Zhenjiang, Jiangsu Province, 213017, People’s Republic of China, Email houyz@ujs.edu.cn Qian Liu, Department of Oncology, Wujin Hospital Affiliated with Jiangsu University, Changzhou, Jiangsu Province, 213017, People’s Republic of China, Email liuqian@wjrmyy.cn
Abstract: SLC7A11 (xCT) is a key subunit of the cysteine/glutamate transporter (system xc −), which is crucial for maintaining cellular redox homeostasis (especially glutathione synthesis) and regulating Ferroptosis. It is highly expressed in various malignant tumors and is a key factor leading to treatment resistance, making it an important anti-cancer target. This review systematically summarizes the complex multi-level regulatory network of SLC7A11: at the transcriptional level, key factors form precise regulatory hubs: the KEAP1/NRF2 pathway directly activates SLC7A11 transcription, endowing cancer cells with antioxidant and anti ferroptotic abilities; P53 acts as a core inhibitory factor, and its activity state (activated by STEAP3 iron overload or regulated by Gankyrin/DM2 degradation) directly determines the intensity of inhibition of SLC7A11; ATF4 integrates endoplasmic reticulum stress, oxidative damage, and epigenetic signals (such as SIRT3/KDM3B/KDM4A), and bidirectionally regulates SLC7A11 transcription. Epigenetic regulation involves RNA m6A modification (ALKBH5/FTO reduces stability, METTL3/IGF2BP3 enhances stability) and histone modification (BAP1/PRC1 inhibits through H2Aub). After translation, the stability of SLC7A11 protein is strictly regulated by ubiquitination (SOCS2/HECTD3 promotes degradation, OTUB1/TCF12 inhibits degradation) and palmitoylation (ZDHHC8/DUXAP8 antagonizes degradation). Of particular importance is that non coding RNAs indirectly release their inhibition of SLC7A11 mRNA by acting as “molecular sponges” to adsorb specific miRNAs, profoundly affecting tumor progression and resistance to ferroptosis. This study reveals how cancer cells abnormally upregulate SLC7A11 by hijacking multi-level mechanisms, gaining strong antioxidant/anti ferroptotic abilities, which are the core basis for their survival, proliferation, and resistance to treatment. This study also identified SLC7A11 as a convergence point for multiple key pathways, making it an ideal hub target for intervening in cancer and overcoming drug resistance.
Keywords: SLC7A11, ferroptosis, non-coding RNA, TP53, epigenetic regulation